Prothena Corporation plc (PRTA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Prothena Corporation plc (PRTA) closed at USD 8.37 on 2026-10-14, a change of -20.6 % over the past year, with a market capitalization of USD 436.36M.

Prothena Corporation plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Prothena Corporation plc key figures

Previous close

USD 8.37 (2026-10-14)

1-year change

-20.6 %

Market cap

USD 436.36M

Enterprise value

USD 155.16M

P/E ratio (trailing)

-10.24

P/E ratio (forward)

-6.46

EPS (trailing)

-0.83

EPS (forward)

-1.32

PEG ratio

n/a

Price to book

1.53

Revenue growth

-77.1 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

17.58

Employees

67

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Prothena Corporation plc and compare it with other stocks.